CTXR vs CYTK

Citius Pharmaceuticals, Inc. vs Cytokinetics, Incorporated — Valuation Comparison 2026

By CirclFi Research Team · Updated 2026-06-03 · Data from SEC EDGAR, FRED & GDELT

Quick Summary — CYTK scores higher on quality with 5.9/10 vs CTXR's 3.0/10. CTXR trades at $0.60 while CYTK trades at $70.91. Both analyzed daily using SEC EDGAR data across 13 institutional models.

CTXR

Biotechnology
Citius Pharmaceuticals, Inc.
Quality
3.0
out of 10
Value Trap
30
LOW
Price
$0.60
Last close
Models
6/13
Active
VS

CYTK

Biotechnology
Cytokinetics, Incorporated
Quality
5.9
out of 10
Value Trap
33
LOW
Price
$70.91
Last close
Models
9/13
Active
CTXR
2 models active
Quality 3.0/10 — below average
CYTK
2 models active
Limited to 2/13 visible models

CTXR vs CYTK — Fair Value Comparison

CTXR
$0$0$0$1 Price$0.60 ML-RIV$0.33 (-53.3%) Dynamic N…$0.11 (-84.9%)
CYTK
$0$28$56$84 Price$70.91 Bayesian …$19.39 (-72.7%) Earnings …$21.45 (-67.2%)
Market Price Model 1 Model 2

Model-by-Model Comparison

ModelType CTXR Fair ValueCTXR Upside CYTK Fair ValueCYTK Upside
Bayesian DCF Intrinsic $19.39 -72.7%
Earnings Power Value Intrinsic $21.45 -67.2%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.33 -53.3% $14.37 -81.7%
Dynamic NAV Asset-Based $0.11 -84.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%

CTXR vs CYTK — Which Stock Is More Undervalued in 2026?

CYTK scores higher with a 5.9/10 quality rating vs CTXR's 3.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do CTXR and CYTK Valuations Compare?

CTXR currently trades at $0.60 while CYTK trades at $70.91. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily for both companies.

Quality of Company: CTXR vs CYTK

CTXR earns a Quality of Company score of 3.0/10 compared to CYTK's 5.9/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: CTXR vs CYTK

CTXR carries a LOW value trap risk (30/100) while CYTK shows LOW risk (33/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Biotechnology

Both CTXR and CYTK operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare CTXR vs CYTK differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo  ·  FactSet: ~$1,000/mo  ·  CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

See all Biotechnology stocks →